Antifracture Efficacy of 5- or 10-Yearly Zoledronate in Women Aged 50 to 60 Years: Secondary Analyses of a Randomized Trial

• by Mark J Bolland, Zaynah Nisa, Anna Mellar, Chiara Gasteiger, Veronica Pinel, Borislav Mihov, Sonja Bastin, Andrew Grey, Ian R Reid, Greg Gamble, Anne Horne

• October 18, 2025

Osteoimmuno-brain axis: a bridge connecting osteoporosis and cognitive decline and its clinical significance in dementia and Alzheimer’s disease

• by Guang Xu, Zheng Cheng, Yali Zhou, Liang Guo, Huihua Zhu, Zuojia Shen

• June 24, 2026

Medical Oddities: Natural Doesn't Always Mean Safe

From the gym to the kitchen to romance, these studies challenge everyday assumptions.

• by Teraya Smith

• July 15, 2026

• 4 min

Beyond Bone Density: How Fracture Risk Is Changing Osteoporosis Management

As osteoporosis treatment continues to evolve, clinicians are moving beyond bone mineral density scores alone and placing greater emphasis on fracture risk when making therapeutic decisions

• by

• July 8, 2026

• 7 min